HC Advisors’s TG Therapeutics TGTX Stock Holding History

HC Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-11,500	Closed	-$68K	–	90
2022 Q3	$68K	Buy	+11,500	New	+$75.4K	0.05%	83
2021 Q1	–	Sell	-12,834	Closed	-$668K	–	99
2020 Q4	$668K	Buy	+12,834	New	+$434K	0.46%	36

Other funds holding TGTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

HC Advisors's TGTX Position: Q4 2022 in Review

HC Advisors sold out of TG Therapeutics (TGTX) in Q4 2022, closing a stake of 11,500 shares — an estimated $68K sold.

HC Advisors first reported a position in TGTX in Q4 2020 and held it in 2 quarters. The position peaked at $668K in Q4 2020. 198 funds tracked by Wall St. Rank hold TGTX as of Q4 2022.

HC Advisors reported no remaining TG Therapeutics position as of Q4 2022 after selling out during the quarter.
HC Advisors sold 11,500 TG Therapeutics shares in Q4 2022, an estimated $68K.
HC Advisors first reported a position in TG Therapeutics in Q4 2020 and held it in 2 quarters.
HC Advisors's TG Therapeutics position peaked at $668K in Q4 2020.
198 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2022.

Based on HC Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.